Feed TGTX
TG

TG Therapeutics

TGTX · NASDAQ

$57.16 +0.47% (+$0.27)
1M +1.54%
Market Cap $8.75B
P/E Ratio 19.82x
Div. Yield -
ROE 72.30%

Bulios Fair Price

$38.07

33.4% downside

Current Price

$57.16

Undervalued Fair Value Overvalued

According to Bulios Fair Price, TGTX is currently overvalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Moderate
4/9
Valuation
29 /100
Expensive
P/S 10.94x
P/E 19.82x
P/B 14.49x
Growth
100 /100
Growing
Book val. growth 122.81%
Rev. growth 504.86%
FCF growth N/A
Profitability
63 /100
Moderate
Op. margin 17.05%
Gross margin 82.36%
FCF margin 0.07%
Quality
91 /100
Excellent
ROA 26.93%
ROIC 43.15%
Asset turnover 0.49x
Debt
58 /100
Moderate
Int. coverage 3.57x
Debt/Equity 1.25x
Net debt/EBITDA 2.03x
Stability
13 /100
Unstable
EPS volatility 956.11%
Beta 1.66x
Profitable years 3

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about TGTX
Online

About the company

TG Therapeutics, Inc. (TGTX) is a biotechnology company specializing in the development of therapeutic products in the fields of oncology and autoimmune diseases. The company focuses on discovering and developing innovative treatment approaches that could improve the quality of life for patients suffering from these diseases. TG Therapeutics, Inc. (TGTX) shares may be suitable for investors seeking opportunities in the biotechnology sector and keeping an eye on advancements in the treatment of oncological and autoimmune diseases.

Sector

Healthcare

Industry

Biotechnology

CEO

Michael S. Weiss

Employees

399

Headquarters

Morrisville

Upcoming events

02 NOV

Earnings

Upcoming earnings report

41d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.